{"title":"Three-year post-recurrence survival outcome by leukopenia grade 2+ during systemic chemotherapy in recurrent cervical cancer.","authors":"Pornpawee Wangsatidtongbai, Rakchai Buhachat, Ekasak Thiangphak","doi":"10.5468/ogs.26032","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the association between grade ≥2 chemotherapy-induced leukopenia (CIL) and 3-year post-recurrence survival (PRS) in patients with recurrent cervical cancer (CC) undergoing systemic chemotherapy.</p><p><strong>Methods: </strong>We conducted a retrospective comparative cohort study of patients with recurrent CC who received ≥3 cycles of systemic chemotherapy at a tertiary referral center between January 2000 and June 2022. Complete serial blood counts were performed for each cycle. Patients were classified according to the development of grade ≥2 leukopenia (white blood cell count <3,000 cells/μL) within the first 3 cycles. Three-year PRS was analyzed using Kaplan-Meier estimates and Cox proportional hazards models.</p><p><strong>Results: </strong>Among 164 patients (mean age 52.4±11.0 years), leukopenia G2+ occurred in 29 patients (17.7%). Median 3-year PRS was significantly longer in the leukopenia G2+ group than in the non-leukopenia G2+ group (28.9 vs. 17.5 months). The 3-year PRS rates were 38.8% and 16.9%, respectively (P=0.022). On univariate analysis, longer intervals from complete clinical remission to recurrence, platinum regimens, and grade ≥2 leukopenia were associated with improved survival. Multivariate analysis confirmed that leukopenia conferred a 47% reduction in mortality risk (hazard ratio, 0.53; 95% confidence interval, 0.31-0.91; P= 0.021).</p><p><strong>Conclusion: </strong>CIL during early treatment cycles was independently associated with superior survival in patients with recurrent CC. In the absence of infectious complications, leukopenia may reflect adequate pharmacodynamic drug exposure and host treatment response. It should be interpreted as a post-hoc prognostic indicator, supporting its potential role as a pragmatic surrogate marker of chemotherapy efficacy.</p>","PeriodicalId":37602,"journal":{"name":"Obstetrics and Gynecology Science","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics and Gynecology Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5468/ogs.26032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to evaluate the association between grade ≥2 chemotherapy-induced leukopenia (CIL) and 3-year post-recurrence survival (PRS) in patients with recurrent cervical cancer (CC) undergoing systemic chemotherapy.
Methods: We conducted a retrospective comparative cohort study of patients with recurrent CC who received ≥3 cycles of systemic chemotherapy at a tertiary referral center between January 2000 and June 2022. Complete serial blood counts were performed for each cycle. Patients were classified according to the development of grade ≥2 leukopenia (white blood cell count <3,000 cells/μL) within the first 3 cycles. Three-year PRS was analyzed using Kaplan-Meier estimates and Cox proportional hazards models.
Results: Among 164 patients (mean age 52.4±11.0 years), leukopenia G2+ occurred in 29 patients (17.7%). Median 3-year PRS was significantly longer in the leukopenia G2+ group than in the non-leukopenia G2+ group (28.9 vs. 17.5 months). The 3-year PRS rates were 38.8% and 16.9%, respectively (P=0.022). On univariate analysis, longer intervals from complete clinical remission to recurrence, platinum regimens, and grade ≥2 leukopenia were associated with improved survival. Multivariate analysis confirmed that leukopenia conferred a 47% reduction in mortality risk (hazard ratio, 0.53; 95% confidence interval, 0.31-0.91; P= 0.021).
Conclusion: CIL during early treatment cycles was independently associated with superior survival in patients with recurrent CC. In the absence of infectious complications, leukopenia may reflect adequate pharmacodynamic drug exposure and host treatment response. It should be interpreted as a post-hoc prognostic indicator, supporting its potential role as a pragmatic surrogate marker of chemotherapy efficacy.
期刊介绍：
Obstetrics & Gynecology Science (NLM title: Obstet Gynecol Sci) is an international peer-review journal that published basic, translational, clinical research, and clinical practice guideline to promote women’s health and prevent obstetric and gynecologic disorders. The journal has an international editorial board and is published in English on the 15th day of every other month. Submitted manuscripts should not contain previously published material and should not be under consideration for publication elsewhere. The journal has been publishing articles since 1958. The aim of the journal is to publish original articles, reviews, case reports, short communications, letters to the editor, and video articles that have the potential to change the practices in women''s health care. The journal’s main focus is the diagnosis, treatment, prediction, and prevention of obstetric and gynecologic disorders. Because the life expectancy of Korean and Asian women is increasing, the journal''s editors are particularly interested in the health of elderly women in these population groups. The journal also publishes articles about reproductive biology, stem cell research, and artificial intelligence research for women; additionally, it provides insights into the physiology and mechanisms of obstetric and gynecologic diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
